GHRS GH Research PLC
USHealthcareAs of 2026-07-10 16:00
Why GHRS matters now
GH Research PLC (GHRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $26.51 with -2.54% on the session and $1.82B in market capitalization; recent performance reads 1-month +1.37% and YTD +75.12%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.0M, and EPS of $-0.31. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.1%.
The latest indexable market news headline is "GH Research Announces Publication of Phase 2a Postpartum Depression Results" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $39.00; recent insider activity includes Moore Duncan filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.24
P/S
0.00
EV/EBITDA
-22.96
DCF Value
$3.99
FCF Yield
-3.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-19.8%
ROA
-20.5%
ROIC
-25.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.0M | $-0.31 |
| Q4 2025 | $0.00 | $-14.1M | $-0.23 |
| FY 2025 | $0.00 | $-48.3M | $-0.79 |
| Q3 2025 | $0.00 | $-14.0M | $-0.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$40.57
Target (Median)
$39.00
Target Range
$32.00 - $65.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IE
Exchange
—
Beta
1.31
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.